Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Humira Side Effects Could Result In Breast Cancer Lawsuits

Humira | Lawsuits, Lawyers | Side Effects: Skin Cancer, Gastrointestinal Cancer, Breast Cancer, Lung Tumors, Inflammation, Swelling, Pain, Joint Damage

On May 17, 2006 a new study discovered that patients taking Humira face triple the risk of developing several kinds of cancer and double the risk of getting severe infections. Humira (generic: Adalimumab) is manufactured by Abbott Laboratories and is prescribed to combat Rheumatoid arthritis. Humira was granted FDA approval on December 31, 2002.

Humira is in the same class of drugs as Enbrel and Remicade. These drugs are called anti-TNF drugs or TNF blocker drugs. TNF is a small protein called a cytokine, which has a major role in the regulation of the immune system. Anti-TNF drugs confine TNF and obstruct the reaction, which causes the abnormal joint inflammation.

In rheumatoid arthritis, TNF levels are very high, resulting in:

  • Inflammation
  • Swelling
  • Pain
  • Joint damage

Mayo Clinic Study

The findings of this new study can be found in the May 17, 2006 issue of the Journal of the American Medical Association. The Mayo Clinic study found an apparent link to other cancers, including skin, gastrointestinal, breast and lung tumors. Eric Matteson, a professor at the Mayo Clinic in Rochester, Minn., and an author of the study, stated that physicians might well expect to see one additional case of cancer develop within 6 to 12 months of treatment for every 154 patients who take the drugs. Doctors could expect to see one serious infection, such as pneumonia, within 3 to 12 months for every 59 patients treated. Less than 1% of patients in the study developed cancer. The Mayo Clinic study found an apparent link to other cancers, including skin, gastrointestinal, breast and lung tumors. Anti-TNF antibody drugs are one of the fastest-growing prescription classes in the nation.

Legal Help for Humira Users

If you or a loved one took Humira and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


HumiraRSS Feed

Legionella, Listeria Infections Added to Black Box Warning for TNFa Blockers

Sep 8, 2011 | Parker Waichman LLP
Patients treated with Remicade, Enbrel, Humira, Cimzia and Simponi are at an increased risk of developing Listeria or Legionella infections.  Such drugs, known as Tumor Necrosis Factor-alpha (TNFa) blockers, are immunosuppressive drugs, and it was already known that such medications increased a patient’s risk of serious infections.In a Drug Safety Communication issued yesterday, the U.S. Food & Drug Administration (FDA) announced that information regarding Legionella and Listeria...

FDA Releases More Humira, Enbrel, Remicade Info

Sep 1, 2009 | Parker Waichman LLP
Federal regulators have released  more information regarding cancers associated with drugs like Humira, Enbrel, and Remicade.  Last month, the Food & Drug Administration  (FDA) had mandated that the Black Box  Warnings on these drugs - known as TNF blockers -   highlight their possible  association with lymphoma and other cancers in children and teens.In a  supplementary "Question and Answer" document released yesterday, the FDA provided more...

Simponi Carries Risk of Possibly Fatal Fungal Infections

May 29, 2009 | Parker Waichman LLP
Simponi, a new rheumatoid arthritis drug, can cause severe and potentially fatal fungal infections, according to a new warning released yesterday by the Food & Drug Administration (FDA). Because of this risk, the agency said that when  making a decision to use Simponi, doctors must balance the potential benefits with the potential risks of therapy based upon a patient’s individual need.Simponi is one of a class of drugs known as TNF-alpha blockers.  Such medications work by...

Humira, Kineret, Remicade May Raise the Risk of Developing Shingles

Feb 18, 2009 | Parker Waichman LLP
Shingles seems to be one of the adverse reactions to rheumatoid arthritis sufferers taking Humira, Kineret, and Remicade.  WebMD Health News reported that these drugs, in the TNF-alpha blocker class, nearly doubled the risk of shingles—herpes zoster—in a German study involving 5,040 patient participants.Humira, Kineret, and Remicade each increased the risk of developing shingles by 80 percent according to Anja Strangfeld, MD from the German Rheumatism Research Center in Berlin,...

FDA Warning Over Humira Ad

Dec 24, 2008 | Parker Waichman LLP
Abbott Laboratories is in more hot water over its Humira advertising.  Federal regulators warned Abbott about its advertisements for the company's psoriasis drug, saying the ad is misleading and makes claims not supported by scientific evidence.  According to  Dow Jones, the Humira (generic: Adalimumab) ad cited claims the medication is approved for patients with moderate to severe chronic plaque psoriasis.  According to a U.S. Food and Drug Administration (FDA) letter dated...

More Humira News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo